New Analysis Finds No Link Between Gout Flares and Cardiovascular Events
A secondary analysis of the CARES trial indicates that gout flares do not increase the risk of cardiovascular events in patients undergoing urate-lowering therapy.
🥗NutritionPhoto: medpagetoday.com
Key points
- Secondary analysis of the CARES trial shows no link between gout flares and cardiovascular events.
- The study population consisted of patients at high risk for cardiovascular disease receiving urate-lowering therapy.
- Results remained consistent across multiple subgroup analyses and flare definitions.
A recent secondary analysis of the randomized CARES trial has found no evidence of an association between gout flares and subsequent cardiovascular events among patients receiving treat-to-target urate-lowering therapy. The findings, presented at the American College of Rheumatology annual meeting, suggest that the inflammation caused by acute gout flares does not necessarily trigger major adverse cardiovascular events (MACE) in this specific clinical population.
Researchers examined data from the CARES trial, which focused on patients with known cardiovascular disease or significant risk factors. Participants were randomized to receive either allopurinol or febuxostat, with dosages adjusted to reach specific urate targets. By comparing over 650 patients who experienced MACE against more than 3,200 controls, the study found no increased odds of gout flares among those who suffered cardiovascular events.
What to know: While previous observational research suggested a potential link between gout flares and heart health, this study provides reassurance for clinicians using standard gout management protocols. The analysis remained consistent across various sensitivity checks, including different definitions of gout flares and periods of intense treatment initiation.
The findings suggest that clinicians can continue to recommend treat-to-target urate-lowering therapy without the concern that these flares are inducing cardiovascular events.
Patients should always consult with their healthcare provider to discuss their specific cardiovascular risk profile and appropriate gout management strategies. Further research is needed to reconcile these findings with earlier observational data and to better understand the complex relationship between anti-inflammatory medications and cardiovascular outcomes.
Source medpagetoday.com — medpagetoday.com/meetingcoverage/acrvideopearls/123944 ↗
Read next
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…
🏥Public HealthRecall Issued for Generic Propranolol Over Potential Metal Contamination
Breckenridge Pharmaceutical has initiated a voluntary recall of one lot of generic propranolol capsules due to the potential presence of metal fragments.